HUP0401283A2 - Annellált pirrolvegyületek alkalmazása ízületi porc vagy porc melletti csont elfajulásának kezelésére, és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Annellált pirrolvegyületek alkalmazása ízületi porc vagy porc melletti csont elfajulásának kezelésére, és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0401283A2
HUP0401283A2 HU0401283A HUP0401283A HUP0401283A2 HU P0401283 A2 HUP0401283 A2 HU P0401283A2 HU 0401283 A HU0401283 A HU 0401283A HU P0401283 A HUP0401283 A HU P0401283A HU P0401283 A2 HUP0401283 A2 HU P0401283A2
Authority
HU
Hungary
Prior art keywords
group
formula
aromatic
general formula
treatment
Prior art date
Application number
HU0401283A
Other languages
English (en)
Inventor
Jean-Pierre Pelletier
Johanne Martel-Pelletier
Original Assignee
Merckle Gmbh
Ascentia Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002356099A external-priority patent/CA2356099A1/en
Application filed by Merckle Gmbh, Ascentia Pharma Inc. filed Critical Merckle Gmbh
Publication of HUP0401283A2 publication Critical patent/HUP0401283A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A találmány emlősök ízületi porca és/vagy porc melletti csontjadegenerálódásának vagy destrukciójának kezelésére vagy megelőzéséreszolgáló eljárással foglalkozik, mely eljárás abból áll, hogy akezelendő emlős szervezetébe az (I) általános képletű vegyületnek,gyógyászatilag alkalmazható sójának vagy fiziológiásan hidrolizálhatóészterének terápiásan hatásos mennyiségét juttatják. Előnyös (I)általános képletű vegyület az (la) képletű[6-(4-klór-fenil)-2,2-dimetil-7-fenil-2,3-dihidroxi-1 H-pirrolizini-5-il]-ecetsav (ML3000).Az (I) általános képletben X jelentése CR8R9 általános képletűcsoport, kén- vagy nitrogénatom, NR12 általános képletű csoport vagyC(O); A jelentése CR10R11 általános képletű csoport vagy kötés; R1jelentése adott esetben helyettesített aril-, aromás vagy nem aromásegy vagy kétgyűrűs 1,2 heteroaromot tartalmazó heterociklusos csoport;R2 jelentése adott esetben helyettesített alkil-, cikloalkil-, aril-vagy aromás vagy nem aromás egy vagy kétgyűrűs heterociklusos csoport;R3 jelentése hidrogén- vagy halogénatom, alkil-, HO-alkil-, CHO-,COOH- képletű csoport; B-Y-csoport - ahol B jelentése alkilén- vagyalkenilén csoport, Y jelentése -COOH, SO3H, OPO(OH)2, OP(OH)2-CHO-képletű csoport. Ó
HU0401283A 2001-08-30 2002-08-29 Annellált pirrolvegyületek alkalmazása ízületi porc vagy porc melletti csont elfajulásának kezelésére, és ezeket tartalmazó gyógyszerkészítmények HUP0401283A2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31577301P 2001-08-30 2001-08-30
CA002356099A CA2356099A1 (en) 2001-08-30 2001-08-30 Use of annellated pyrrole compounds in the treatment of articular cartilage or subchondral bone degeneration
PCT/EP2002/009658 WO2003020267A1 (en) 2001-08-30 2002-08-29 Use of annellated pyrrole compounds in the treatment of articular cartilage or subchondral bone degeneration

Publications (1)

Publication Number Publication Date
HUP0401283A2 true HUP0401283A2 (hu) 2004-12-28

Family

ID=25682702

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401283A HUP0401283A2 (hu) 2001-08-30 2002-08-29 Annellált pirrolvegyületek alkalmazása ízületi porc vagy porc melletti csont elfajulásának kezelésére, és ezeket tartalmazó gyógyszerkészítmények

Country Status (11)

Country Link
US (1) US7425573B2 (hu)
EP (1) EP1427410A1 (hu)
JP (1) JP2005504781A (hu)
CN (1) CN1549711A (hu)
BR (1) BR0212244A (hu)
HU (1) HUP0401283A2 (hu)
IS (1) IS7166A (hu)
MX (1) MXPA04001868A (hu)
NZ (1) NZ531226A (hu)
RU (1) RU2303447C2 (hu)
WO (1) WO2003020267A1 (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060040945A1 (en) * 2002-05-17 2006-02-23 Merckle Gmbh Annellated pyrrole compounds as proton pump inhibitors for treating ulcer
US20050129764A1 (en) * 2003-12-11 2005-06-16 Vergez Juan A. Osmotic device containing licofelone
WO2005123130A2 (en) * 2004-06-17 2005-12-29 Osteologix A/S Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor
CA2619608C (en) * 2005-08-18 2016-02-02 Accelalox, Inc. Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
EP1891955A1 (en) * 2006-07-24 2008-02-27 Sanofi-Aventis Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases
EP1884239A1 (en) * 2006-07-28 2008-02-06 Merckle Gmbh Annellated pyrrole compounds for cancer management
NZ592378A (en) * 2008-10-31 2012-09-28 C A I R Biosciences Gmbh Choline and tromethamine salt of licofelone
CA2822357A1 (en) 2010-12-22 2012-06-28 Abbvie Inc. Hepatitis c inhibitors and uses thereof
US8524662B2 (en) 2010-12-28 2013-09-03 Depuy Mitek, Llc Compositions and methods for treating joints
US8398611B2 (en) 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
US8455436B2 (en) 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
US8623839B2 (en) 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
US9682099B2 (en) 2015-01-20 2017-06-20 DePuy Synthes Products, Inc. Compositions and methods for treating joints
WO2016201682A1 (zh) * 2015-06-18 2016-12-22 高雄医学大学 一种医药组合物用于制备促进软骨细胞生成的药物的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4232038A (en) * 1979-08-31 1980-11-04 Syntex (U.S.A.) Inc. 5-Alkylsulfinylbenzoyl- and 5-alkylsulfonylbenzoyl-1,2-dihydro-3H-pyrrolo[1,]pyrrole-1-carboxylic acids
US4704356A (en) * 1984-03-27 1987-11-03 Rush-Presbyterian-St. Luke's Medical Center Method of diagnosing cartilage tissue abnormalities
US5260451A (en) * 1989-05-11 1993-11-09 Merckle Gmbh Substituted pyrrole compounds and use thereof in pharmaceutical compositions
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
US5464609A (en) * 1990-03-16 1995-11-07 The Procter & Gamble Company Use of ketorolac for treatment of oral diseases and conditions
US5310759A (en) * 1992-08-12 1994-05-10 Bockman Richard S Methods of protecting and preserving connective and support tissues
DE4419247A1 (de) 1994-06-01 1995-12-07 Merckle Gmbh Sulfonylierte Pyrrolizincarbonsäureamide und deren Anwendung in der Pharmazie
DE4419315A1 (de) 1994-06-01 1995-12-07 Merckle Gmbh Heteropyrrolizinverbindungen und deren Anwendung in der Pharmazie
DE19624290A1 (de) 1996-06-18 1998-01-02 Merckle Gmbh Verwendungen von Pyrrolizin-Verbindungen in der Pharmazie
DE19624289A1 (de) 1996-06-18 1998-01-02 Merckle Gmbh Pyrrolizin-Verbindungen und deren Verwendung
DE19845446A1 (de) 1998-10-02 2000-04-06 Merckle Gmbh Antiinflammatorische Oxo- und Hydroxyderivate von Pyrrolizinen und deren Verwendung in der Pharmazie
DK1232158T3 (da) 1999-11-23 2004-06-14 Merckle Gmbh Anti-inflammatoriske oxo- og hydroxyderivater af pyrroliziner og anvendelse deraf på det farmaceutiske område
DE10001166A1 (de) * 2000-01-13 2001-07-19 Merckle Gmbh Anellierte Pyrrolverbindungen, diese enthaltende pharmazeutische Mittel und deren Verwendung
DE10004157A1 (de) * 2000-02-01 2001-08-02 Merckle Gmbh Chem Pharm Fabrik 4-Pyridyl-und 2,4-Pyrimidinyl-substituierte Pyrrolderivate und ihre Anwendung in der Pharmazie

Also Published As

Publication number Publication date
IS7166A (is) 2004-02-27
WO2003020267A1 (en) 2003-03-13
RU2303447C2 (ru) 2007-07-27
JP2005504781A (ja) 2005-02-17
RU2004109227A (ru) 2005-04-10
US7425573B2 (en) 2008-09-16
MXPA04001868A (es) 2005-10-05
US20050004108A1 (en) 2005-01-06
NZ531226A (en) 2006-07-28
BR0212244A (pt) 2004-10-05
CN1549711A (zh) 2004-11-24
EP1427410A1 (en) 2004-06-16

Similar Documents

Publication Publication Date Title
HUP0401283A2 (hu) Annellált pirrolvegyületek alkalmazása ízületi porc vagy porc melletti csont elfajulásának kezelésére, és ezeket tartalmazó gyógyszerkészítmények
ATE354563T1 (de) Sulfonderivate zur hemmung von gamma-secretase
NO2007010I1 (no) Sitagliptin, eventuelt i form av et farmasoytisk akseptabelt salt
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
RS99203A (en) Pyrrolopyrimidines as protein kinase inhibitors
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
GB0128108D0 (en) Therapeutic use
ATE417832T1 (de) Hexahydrodiazepinone als inhibitoren des dipeptidylpeptidase-iv zur behandlung bzw. prävention von diabetes
ATE384068T1 (de) Thiazolo(4,5-d)pyrimidinverbindungen zur behandlung von rheumathoider arthritis
ATE265857T1 (de) Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie
WO2004098617A3 (en) Controlled release composition containing a strontium salt
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
DE60027209D1 (de) Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen
DE60233433D1 (de) PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN
DE69707372T2 (de) Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne
PL378939A1 (pl) Związki z działaniem nootropowym, ich wytwarzanie, zawierające je kompozycje farmaceutyczne i ich zastosowanie
WO2004067027A3 (en) Osteogenic composition
DE602004031631D1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
ATE400277T1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
DE60111574D1 (de) Bisphosphonate-enthaltenden zusammensetzungen zur vorbeugung und/oder heilung von metabolischen knochenkrankheiten, verfahren zu ihren herstellung und benutzung dieser zusammensetzungen
DE69402004T2 (de) Beta-mercapto-propanamidderivate verwendbar zur Behandlung kardiovaskularer Krankheiten oder Erkrankungen
DE50109320D1 (de) Verwendung von 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz
DE69719095D1 (de) Gallensauersälze mit physiologisch aktiven metalle und ihre verwendung zur therapeutischen behandlung
EA200200656A1 (ru) НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-е]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ
SG146685A1 (en) Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees